<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">2983306R</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3565</journal-id>
<journal-id journal-id-type="nlm-ta">Epilepsia</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsia</journal-id>
<journal-title-group>
<journal-title>Epilepsia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0013-9580</issn>
<issn pub-type="epub">1528-1167</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28675558</article-id>
<article-id pub-id-type="pmc">5679081</article-id>
<article-id pub-id-type="doi">10.1111/epi.13779</article-id>
<article-id pub-id-type="manuscript">NIHMS916357</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical studies and anti-inflammatory mechanisms of treatments</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>French</surname>
<given-names>Jacqueline A.</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koepp</surname>
<given-names>Matthias</given-names>
</name>
<xref ref-type="aff" rid="A2">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naegelin</surname>
<given-names>Yvonne</given-names>
</name>
<xref ref-type="aff" rid="A3">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vigevano</surname>
<given-names>Federico</given-names>
</name>
<xref ref-type="aff" rid="A4">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Auvin</surname>
<given-names>Stéphane</given-names>
</name>
<xref ref-type="aff" rid="A5">¶</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rho</surname>
<given-names>Jong M.</given-names>
</name>
<xref ref-type="aff" rid="A6">**</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>Evan</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Devinsky</surname>
<given-names>Orrin</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olofsson</surname>
<given-names>Peder S.</given-names>
</name>
<xref ref-type="aff" rid="A7">††</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dichter</surname>
<given-names>Marc A.</given-names>
</name>
<xref ref-type="aff" rid="A8">‡‡</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>*</label>Comprehensive Epilepsy Center, NYU Langone School of Medicine, New York City, New York, U.S.A</aff>
<aff id="A2">
<label>†</label>Institute of Neurology, University College London, London, United Kingdom</aff>
<aff id="A3">
<label>‡</label>Department of Neurology, University Hospital Basel, Basel, Switzerland</aff>
<aff id="A4">
<label>§</label>Neurology Unit, Department of Neuroscience, Bambino Gesù Children Hospital, Rome, Italy</aff>
<aff id="A5">
<label>¶</label>Pediatric Neurology, Robert Debré University Hospital, Paris, France</aff>
<aff id="A6">
<label>**</label>Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada</aff>
<aff id="A7">
<label>††</label>Center for Bioelectronic Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden</aff>
<aff id="A8">
<label>‡‡</label>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A</aff>
<author-notes>
<corresp id="FN1">Address correspondence to Jacqueline A. French, MD, NYU Comprehensive Epilepsy Center, New York, NY 10016, U.S.A. <email>jacqueline.french@nyumc.org</email> and Marc A. Dichter, MD PhD, Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, U.S.A. <email>dichter@mail.med.upenn.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Disclosure</bold>
</p>
<p>The authors declare that they have no conflicts of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>58</volume>
<issue>Suppl 3</issue>
<fpage>69</fpage>
<lpage>82</lpage>
<!--elocation-id from pubmed: 10.1111/epi.13779-->
<abstract>
<title>Summary</title>
<p id="P1">In this exciting era, we are coming closer and closer to bringing an anti-inflammatory therapy to the clinic for the purpose of seizure prevention, modification, and/or suppression. At present, it is unclear what this approach might entail, and what form it will take. Irrespective of the therapy that ultimately reaches the clinic, there will be some commonalities with regard to clinical trials. A number of animal models have now been used to identify inflammation as a major underlying mechanism of both chronic seizures and the epileptogenic process. These models have demonstrated that specific anti-inflammatory treatments can be effective at both suppressing chronic seizures and interfering with the process of epileptogenesis. Some of these have already been evaluated in early phase clinical trials. It can be expected that there will soon be more clinical trials of both “conventional, broad spectrum” anti-inflammatory agents and novel new approaches to utilizing specific anti-inflammatory therapies with drugs or other therapeutic interventions. A summary of some of those approaches appears below, as well as a discussion of the issues facing clinical trials in this new domain.</p>
</abstract>
<kwd-group>
<kwd>Antiepileptogenesis</kwd>
<kwd>Ketogenic diet</kwd>
<kwd>Fingolimod</kwd>
<kwd>Endocannabinoid system</kwd>
<kwd>Vagus nerve stimulation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>